» Articles » PMID: 18261605

Effects of Spironolactone in an Experimental Model of Chronic Cyclosporine Nephrotoxicity

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2008 Feb 12
PMID 18261605
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cyclosporine (CsA)-associated nephrotoxicity is a long-term complication in transplant patients. Chronic CsA nephrotoxicity is associated with renal fibrosis and hyaline arteriolopathy. The aim of this study was to investigate the effect of spironolactone on functional and structural alterations as well as on platelet-derived growth factor B (PDGF-B) and transforming growth factor (TGF) beta expression induced by CsA in a rat model of chronic CsA nephrotoxicity.

Materials And Methods: Twenty-four rats were divided into 3 groups. Group 1 (G1) received vehicle only (V); G2, CsA (15 mg/kg/d; CsA) by intraperitoneal (IP) injection; and G3, a similar CsA dosage + spironolactone (20 mg/kg/d; CsA + Ald.) by the oral route. At the end of 28 days, glomerular filtration rate (GFR) and blood CsA levels were measured as well as histopathological and immunohistochemical analyses performed on renal tissue.

Results: Mean CsA trough levels in G2 and G3 were both above 2000 ng/mL. In G2, GFR was lower than G1 and G3 (0.35 +/- 0.05, 1.64 +/- 0.24, and 1.20 +/- 0.25 mL/min, respectively; P < .001). There was a significantly increased number of arteriolopathic changes in G2 and G3 vs G1 (16% +/- 3.7%, 15% +/- 6.8%, 3% +/- 1.2%, respectively; P < .001). Interstitial fibrosis was significantly increased in G2 vs G1 and G3 (52%, 0%, 27%, respectively; P < .05). Marked by up-regulated PDGF-B and TGF beta expressions were observed in G2 vs G1 or G3: 100%, 0%, 37.5%, respectively, for PDGF-B (P < .001) and 87.5%, 0%, 12.5%, respectively, for TGF beta (P < .001).

Conclusion: Our results suggested that chronic CsA nephrotoxicity may be mitigated by aldosterone receptor blockade which seemed to be associated with down-regulation of PDGF-B and TGF beta expression.

Citing Articles

Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): A Randomized Placebo-Controlled Clinical Trial.

Mortensen L, Jespersen B, Helligsoe A, Tougaard B, Cibulskyte-Ninkovic D, Egfjord M Clin J Am Soc Nephrol. 2024; 19(6):755-766.

PMID: 38416033 PMC: 11168825. DOI: 10.2215/CJN.0000000000000439.


RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.

Koszegi S, Molnar A, Lenart L, Hodrea J, Balogh D, Lakat T J Physiol. 2018; 597(1):193-209.

PMID: 30324679 PMC: 6312411. DOI: 10.1113/JP277002.


Altered Expression of Phox2 Transcription Factors in the Locus Coeruleus in Major Depressive Disorder Mimicked by Chronic Stress and Corticosterone Treatment In Vivo and In Vitro.

Fan Y, Chen P, Raza M, Szebeni A, Szebeni K, Ordway G Neuroscience. 2018; 393:123-137.

PMID: 30315878 PMC: 6246807. DOI: 10.1016/j.neuroscience.2018.09.038.


The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).

Mortensen L, Thiesson H, Tougaard B, Egfjord M, Fischer A, Bistrup C BMC Nephrol. 2018; 19(1):105.

PMID: 29724188 PMC: 5934785. DOI: 10.1186/s12882-018-0885-6.


Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity?.

Mortensen L, Bistrup C, Thiesson H Front Med (Lausanne). 2017; 4:210.

PMID: 29226122 PMC: 5705552. DOI: 10.3389/fmed.2017.00210.